期刊文献+

^(131)I-抗-c-erbB-2单抗对卵巢癌细胞SKOV3的抑制作用

The inhibitive effect of ^(131)I-anti-c-erbB-2-McAb on ovarian carcinoma
下载PDF
导出
摘要 目的 观察1 .31 I标记针对癌蛋白p185为靶点的单克隆抗体在体外对卵巢癌细胞的抑制作用。方法 用氯胺T法1 .31 I标记抗 c erbB 2单克隆抗体 (anti c erbB 2 McAb) ,取不同浓度的1 .31 I anti c erbB 2 McAb与SKOV3细胞共同培养 ,以流式细胞术检测其对SKOV3细胞生长的抑制作用。结果 1. 31 I anti c erbB 2 McAb在体外可明显抑制SKOV3细胞 ,1 31 I nmIgG的抑制作用较弱 ,未标记的anti c erbB 2 McAb对SKOV3细胞的生长几乎没有抑制作用。结论 1. 31 I anti c erbB 2 McAb能有效抑制肿瘤细胞生长 ,有可能用于卵巢癌的免疫导向治疗。 Objective To observe the inhibitive effect of anti-oncoprotein monoclonal antibody labeled with 131I on ovarian carcinoma cell line, SKOV3. Methods Anti-c-erbB-2 monoclonal antibody (McAb) was labeled with 131I using Chloramine-T. SKOV3 cells were cultured with 131I-anti-c-erbB-2-McAb, and the inhibition was detected with flow cytometry. Results 131I-anti-c-erbB-2-McAb could inhibit the growth of SKOV3 cells, the effect of 131I-normal murine IgG (nmIgG, as control agent) was rather poor, while anti-c-erbB-2-McAb without 131I could hardly inhibit the growth of SKOV3 cells in vitro. Conclusion 131I-anti-c-erbB-2-McAb can obviously inhibit the growth of the tumor cell line and is promising to be used in the targeting radioimmunotherapy.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2005年第1期41-42,共2页 Chinese Journal of Nuclear Medicine
基金 广东省科委攻关基金资助项目 (A0 0 0 0 990 2 9)
关键词 ^131 SKOV3 C-ERBB-2 抑制作用 抗-C 卵巢癌细胞 体外 P185 细胞生长 Ovarian neoplasms Tumor cells, cultured Antibodies, monoclonal Radioimmunotherapy Iodine radioisotopes
  • 相关文献

参考文献5

二级参考文献74

  • 1[1]Seidman AD,Fornier M,Esteva F,et al.Final report:weekly Herceptin and Taxol for metastatic breast cancer:analysis of efficacy by HER-2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridization (FISH)][J].Proc Am Soc Clin Oncol,2000,19∶319.
  • 2[2]Nicholson BP,Thor AD,Goldstein LJ,et al.Weekly docetaxel and rhumabher combination therapy as first or second line treatment for metastatic breast cancer[J].Proc Am Soc Clin Oncol,2000,19∶549.
  • 3[3]Burstein HJ,Kuter I,Richardson PG,et al.Herceptin and Vinorelbine for HER-2 positive metastatic breast cancer:a phase II study[J].Proc Am Soc Clin Oncol,2000,19∶392.
  • 4[4]Sliwkowski MX,Lofgren JA,Lewis GD,et al.Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)[J].Semin Oncol,1999,26(Suppl 12)∶S60-S70.
  • 5[5]Salomon DS,Brandt R,Ciardiello F,et al.Epidermal growth factor-related peptides and their receptors in human malignancies[J].Crit Rev Oncol Hematol,1995,19∶183-232.
  • 6[6]Wu X,Fan Z,Masui H,et al.Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin[J].J Clin Invest,1995,95∶1897-1905.
  • 7[7]Moyer JD,Barbacci EG,Iwata KK,et al.Induction of apoptosis and cell cycle arrest by CP-358,774,an inhibitor of epidermal growth factor receptor tyrosine kinase[J].Cancer Res,1997,57∶4838-4848.
  • 8[8]Kris MG,Herbst R,Rischin D,et al.Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa),a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)[J].Lung Cancer,2000,29(Suppl 1)∶72(abstract).
  • 9[9]Senzer NN,Soulieres D,Siu L,et al.Phase 2 evaluation of OSI-774,a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck[J].Proc Am Soc Clin Oncol,2001,20∶2a(abstract 6).
  • 10[10]Saltz L,Rubin M,Hochster H,et al.Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor(EGFR)[J].Proc Am Soc Clin Oncol,2001,20∶3a(abstract 7).

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部